Insider · CIK 0001120478

GOLDSTEIN DOV A MD

Reports to the SEC for 10 companies · BETHESDA, MD

sec.gov

Transactions

Companies

Filings

CIK

0001120478

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-07-15	GANXGain Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+25K sh	—	—	25,000
2026-04-23	BIOABioAge Labs, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+3,542 sh	$4.38	+$15.5K	36,575
2026-04-23	BIOABioAge Labs, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−3,542 sh	—	—	155,833
2026-03-01	BIOABioAge Labs, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−3,542 sh	—	—	159,375
2026-03-01	BIOABioAge Labs, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+3,542 sh	$4.38	+$15.5K	33,033
2026-02-17	BIOABioAge Labs, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+110K sh	—	—	110,000
2026-02-01	BIOABioAge Labs, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+3,541 sh	$4.38	+$15.5K	29,491
2026-02-01	BIOABioAge Labs, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−3,541 sh	—	—	162,917
2026-01-16	BIOABioAge Labs, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+3,542 sh	$4.38	+$15.5K	25,950
2026-01-16	BIOABioAge Labs, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−3,542 sh	—	—	166,458
2026-01-13	BIOABioAge Labs, Inc.S Sale	Chief Financial Officer	SSale	−4,440 sh	$19.45	−$86.4K	35,994
2026-01-13	BIOABioAge Labs, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−27K sh	—	—	92,587
2026-01-13	BIOABioAge Labs, Inc.S Sale	Chief Financial Officer	SSale	−11.7K sh	$20.54	−$240K	24,331
2026-01-13	BIOABioAge Labs, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+27K sh	$8.39	+$227K	49,408
2026-01-13	BIOABioAge Labs, Inc.S Sale	Chief Financial Officer	SSale	−8,974 sh	$18.43	−$165K	40,434
2026-01-13	BIOABioAge Labs, Inc.S Sale	Chief Financial Officer	SSale	−1,923 sh	$21.08	−$40.5K	22,408
2026-01-02	COYACoya Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+10K sh	—	—	10,000
2025-08-18	COYACoya Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+17.6K sh	$1.09	+$19.1K	27,557
2025-08-18	COYACoya Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−17.6K sh	—	—	0
2025-06-24	GANXGain Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+15K sh	—	—	15,000
2025-02-25	COYACoya Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+5,000 sh	—	—	5,000
2025-02-18	BIOABioAge Labs, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+170K sh	—	—	170,000
2025-01-01	COYACoya Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+5,000 sh	—	—	5,000
2024-06-24	GANXGain Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+15K sh	—	—	15,000
2024-01-01	COYACoya Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+5,000 sh	—	—	5,000
2023-06-23	GANXGain Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+10.5K sh	—	—	10,500
2023-01-03	COYACoya Therapeutics, Inc. · Warrant to Purchase Common StockP Purchase	Director	PPurchase	+5,000 sh	—	—	5,000
2023-01-03	COYACoya Therapeutics, Inc.P Purchase	Director	PPurchase	+10K sh	—	—	10,000
2022-09-20	GANXGain Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+10.5K sh	—	—	10,500
2022-09-09	NeuBase Therapeutics, Inc.Stock option (right to buy)A Award	Director	AAward	+37.6K sh	—	—	37,600
2021-08-19	NeuBase Therapeutics, Inc.Stock option (right to buy)A Award	Director	AAward	+38.1K sh	—	—	38,135
2021-06-18	NeuBase Therapeutics, Inc.P Purchase	Director	PPurchase	+8,000 sh	$4.75	+$38K	30,000
2021-04-26	NeuBase Therapeutics, Inc.P Purchase	Director	PPurchase	+12K sh	$5.00	+$60K	22,000
2020-09-09	NeuBase Therapeutics, Inc.Stock option (right to buy)A Award	Director	AAward	+14.6K sh	—	—	14,634
2020-04-30	NeuBase Therapeutics, Inc.P Purchase	Director	PPurchase	+10K sh	$6.00	+$60K	10,000
2020-02-28	ADMAADMA BIOLOGICS, INC. · Employee Stock Option (right to buy)A Award	Director	AAward	+15K sh	—	—	15,000
2020-02-28	ADMAADMA BIOLOGICS, INC.A Award	Director	AAward	+7,500 sh	—	—	7,500
2020-02-28	ADMAADMA BIOLOGICS, INC.A Award	Director	AAward	+7,500 sh	—	—	7,500
2019-07-12	NeuBase Therapeutics, Inc.Stock option (right to buy)A Award	Director	AAward	+227K sh	—	—	227,330
2019-03-13	ADMAADMA BIOLOGICS, INC. · Stock Option (right to buy)A Award	Director	AAward	+30K sh	—	—	30,000
2018-06-22	ADMAADMA BIOLOGICS, INC. · Stock Option (right to buy)A Award	Director	AAward	+17.5K sh	—	—	17,500
2018-06-06	ESPREsperion Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	+8,000 sh	—	—	0
2018-06-06	ESPREsperion Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	+5,000 sh	—	—	0
2018-06-06	ESPREsperion Therapeutics, Inc.J Other	Director	JOther	−8,000 sh	—	—	47
2018-06-06	ESPREsperion Therapeutics, Inc.J Other	Director	JOther	−5,000 sh	—	—	8,047
2018-06-06	ESPREsperion Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+8,000 sh	$17.75	+$142K	13,047
2018-06-06	ESPREsperion Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+5,000 sh	$14.42	+$72.1K	5,047
2018-05-23	ESPREsperion Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+10.1K sh	—	—	10,100
2017-12-18	ESPREsperion Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−21.5K sh	—	—	0
2017-12-18	ESPREsperion Therapeutics, Inc.J Other	Director	JOther	−21.5K sh	—	—	47

Recent filings

Accepted (ET)
Jul 174
GOLDSTEIN DOV A MD0001104659-26-084439
SEC(opens sec.gov)
Apr 244
GOLDSTEIN DOV A MD0001120478-26-000013
SEC(opens sec.gov)
Mar 34
GOLDSTEIN DOV A MD0001120478-26-000011
SEC(opens sec.gov)
Feb 194
GOLDSTEIN DOV A MD0001120478-26-000009
SEC(opens sec.gov)
Feb 34
GOLDSTEIN DOV A MD0001120478-26-000007
SEC(opens sec.gov)
Jan 214
GOLDSTEIN DOV A MD0001120478-26-000005
SEC(opens sec.gov)
Jan 154
GOLDSTEIN DOV A MD0001120478-26-000003
SEC(opens sec.gov)
Jan 64
GOLDSTEIN DOV A MD0001193125-26-005023
SEC(opens sec.gov)
Aug 194
GOLDSTEIN DOV A MD0001641172-25-024820
SEC(opens sec.gov)
Jun 254
GOLDSTEIN DOV A MD0001641172-25-016536
SEC(opens sec.gov)

Companies

Address

C/O GAIN THERAPEUTICS, INC. 4800 MONTGOMERY LANE, SUITE 220

BETHESDA, MD, 20814